Sangamo Therapeutics Inc (LTS:0R1D)
$ 1.9196 -0.0403 (-2.06%) Market Cap: 417.29 Mil Enterprise Value: 405.82 Mil PE Ratio: 0 PB Ratio: 10.37 GF Score: 34/100

Q2 2024 Sangamo Therapeutics Inc Earnings Call Transcript

Aug 06, 2024 / 08:30PM GMT
Release Date Price: $1 (+21.26%)
Operator

Good afternoon, and welcome to the Sangamo Therapeutics' second-quarter 2024 teleconference call. Please be advised that today's conference is being recorded.

I would now like to turn the conference over to your speaker today, Louise Wilkie, Vice President of Investor Relations and Corporate Communications. Please go ahead.

Louise Wilkie
Sangamo Therapeutics Inc - Investor Relations

Thank you. Good afternoon, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Prathyusha Duraibabu, Chief Financial Officer; Nathalie Dubois-Stringfellow, Chief Development Officer; Amy Pooler, Head of Research; and Greg Davis, Head of Technology.

Slides from our corporate presentation can be found on our website, sangamo.com, under the Presentations page of the Investors and Media section.

This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot